Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

RepliCel starts phase I trial of autologous fibroblast therapy RCS-01

Sep. 16, 2015

XenoPort reports phase II study data for XP-23829

Sep. 16, 2015

Trevi Therapeutics reports data from phase II/III trial in uremic pruritus

Sep. 15, 2015

FDA approves Humira for moderate to severe hidradenitis suppurativa

Sep. 14, 2015

MediWound completes enrollment in second phase II trial of EscharEx

Sep. 4, 2015

Valeant licenses rights to brodalumab from AstraZeneca

Sep. 1, 2015

Herbal preparation HAT-01 more effective than calcipotriol in psoriasis patients

Aug. 26, 2015

Clinical trial results detailed for tofacitinib in psoriasis

Aug. 25, 2015

Lilly files for approval of ixekizumab in Japan

Aug. 24, 2015

CureXcell not expected to meet primary endpoint in pivotal venous leg ulcer trial

Aug. 20, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...